Navigation Links
Cambrex Receives Notice Regarding NYSE Listing
Date:4/14/2009

ncluding, without limitation, statements regarding expected performance, especially expectations with respect to sales, research and development expenditures, earnings per share, capital expenditures, acquisitions, divestitures, collaborations, or other expansion opportunities. These statements may be identified by the fact that they use words such as "expects," "anticipates," "intends," "estimates," "believes" or similar expressions in connection with any discussion of future financial and operating performance. Any forward-looking statements are qualified in their entirety by reference to the factors discussed throughout the Company's public filings. Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations including, but not limited to, global economic trends, pharmaceutical outsourcing trends, competitive pricing or product developments, government legislation and regulations (particularly environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation disclosed in the Company's public filings, the Company's ability to satisfy the continued listing standards of the New York Stock Exchange, changes in foreign exchange rates, uncollectible receivables, loss on disposition of assets, cancellation or delays in renewal of contracts, lack of suitable raw materials or packaging materials, and the Company's ability to receive regulatory approvals for its products and other factors described under the caption "Risk Factors That May Affect Future Results" in our annual report on Form 10-K for the year ended December 31, 2008. Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, fu
'/>"/>
SOURCE Cambrex Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
2. Cambrex to Announce Fourth Quarter and Full Year 2007 Financial Results on February 14, 2008
3. Cambrex Appoints Steven M. Klosk as President and CEO
4. Cambrex Reports Third Quarter 2008 Results
5. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
6. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
9. IsoTis Receives FDA Clearance for Accell Family of Products
10. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
11. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Bermuda , Sept. 2, 2015 Axovant Sciences ... the treatment of dementia, today announced upcoming presentations at three ... PM at the Baird 2015 Healthcare Conference in ... , Thursday, September 10 at 2:00 PM at the ... at the Millennium Broadway Hotel & Conference Center , ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/v6klp2/nanobiotechnology ... PharmaBiotech,s new report "Nanobiotechnology Applications, Markets ... An increasing use of nanobiotechnology ... anticipated. Nanotechnology will be applied at all ... for optimal delivery to diagnostic applications in ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... compliance, quality systems, analytical testing, education and consulting services for the medical ... medical device products/processes development, design control, validation, quality assurance and regulatory compliance. ...
(Date:9/2/2015)... 02, 2015 Research ... addition of Jain PharmaBiotech,s new report "DNA ... their offering. This report briefly reviews ... technologies, and their applications. Current large and small ... them. Various applications of sequencing are described including ...
Breaking Biology Technology:Axovant Sciences To Present At Upcoming Investor Conferences 2Axovant Sciences To Present At Upcoming Investor Conferences 3Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 4NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 5NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 6NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 7Global DNA Sequencing Technologies Report 2015: Profiles of 130 Companies Involved in Sequencing and their 140 Collaborations 2
... Could Drive Product Adoption in High-Growth Cell Therapy Market ... Dec. 16 BioLife Solutions, Inc. (OTC Bulletin Board: BLFS), ... storage and cryopreservation media products for cells, tissues, and ... series of small animal safety studies at the Seattle-based ...
... Epeius Biotechnologies,Corporation, a leader in tumor-targeted gene ... for the platform targeting technologies and,molecular designs ... cancers and,metastatic lesions that have spread throughout ... and single-agent-efficacy, as well as,overall safety, Epeius ...
... SOUTH SAN FRANCISCO, Calif., Dec. 16 Anesiva,Inc. ... results showing that the Phase 3,trial evaluating Adlea(TM), ... efficacy endpoint of reducing post-surgical,pain versus placebo (p=0.03) ... surgery) at four to 48 hours after surgery. ...
Cached Biology Technology:BioLife Solutions Completes Safety Studies on HypoThermosol(R) and CryoStor(TM) 2BioLife Solutions Completes Safety Studies on HypoThermosol(R) and CryoStor(TM) 3BioLife Solutions Completes Safety Studies on HypoThermosol(R) and CryoStor(TM) 4Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate 2Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery 2Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery 3Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery 4
(Date:8/12/2015)... 12, 2015   MedNet Solutions , an innovative ... of clinical research, is proud to announce that ... SaaS-based eClinical technology platform, has led the way to ... quarters of 2015.   Q2 2015 and Q1 2015 ... by contract value sold in the company,s 15 year ...
(Date:8/12/2015)... Aug. 12, 2015  New research unveiled at ... Android phones to steal users, fingerprints. Information released ... of fingerprint scanners on mobile devices, making the ... secure biometrics on mobile devices, HYPR Corp. recently ... convenient authentication systems with strong cryptographic security. More ...
(Date:8/11/2015)... 11, 2015 Today, ZUK announced its Android ... well as expected revenues in 2015 that relate to sales of ... guidance of approximately 2,200 MSEK for 2015. Jörgen Lantto, ... prominent smartphone manufacturer in China ... selected FPC1 155 for Z1 ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
... The vast majority of patients who had a ... not need mitral valve surgery three years after ... function of the left ventricle (commonly known as ... at the Cardiovascular Research Foundations (CRF) nineteenth annual ...
... marine scientists have been awarded $781,000 by the National ... nutrient pollution from the Mississippi River affects the large ... in the Gulf of Mexico, and consequently its impact ... The funds were awarded to researchers at the University ...
... applying state-of-the-art holographic microscopy to a major marine ... identified the swimming and attack patterns of two ... in the Chesapeake Bay and other waterways. ... Early Edition of Proceedings of the National Academy ...
Cached Biology News:New data shows benefits of MitraClip for patients with mitral regurgitation 2New data shows benefits of MitraClip for patients with mitral regurgitation 3Gulf of Mexico dead zone to be studied by University of Texas at Austin marine scientists 2Researchers view swimming tactics of tiny aquatic predators 2Researchers view swimming tactics of tiny aquatic predators 3
ANTI CORTIS BIN GLOB...
MOUSE ANTI BOVINE WC1:FITC Immunogen: Bovine lymphocytes...
ANTI S. ENTERID LPS...
... This DuoSet ELISA Development kit contains the ... sandwich ELISAs to measure natural and recombinant ... serum. Each kit contains sufficient materials to ... provided that the following conditions are met: ...
Biology Products: